A congenital hypothyroidism complicated by ventricular septal defects which was treated with L-triiodothyronine (L-T3) alone from 1 5/12 to 25 years, is described.
L-triiodothyronine (T3) was originally identified in human plasma by . Shortly thereafter, it was shown that T3 is approximately 3-4 times as effective in the treatment of hypothyroidism as L-thyroxine (T4) and the turnover of T3 is considerably more rapid than that of T4 Lerman et al., 1953) .
Fortunately, we have had synthetic T3 since 1959 and it appeared to be reasonable to use T3, with its rapid onset of action on administration and its effects which disappear more rapidly after its discontinuation, for the treatment of congenital hypothyroidism complicated by ventricular septal defects (VSD).
To the best of our knowledge, no report is yet available on the teatment of congenital hypothyroidism with T3 alone for many years. Thus this case seems to be worth reporting here as a rare case.
Case Report
The patient was referred to the Pediatric Endocrinology Clinic of Chiba University Hospital in June 1961, at the age of 1 5/12 years with suspected congenital hypothyroidism. At 6 months, the pediatric cardiologist made a diagnosis of VSD. He was born by vertex presentation at 38 weeks gestation for placenta praevia. Birth weight was 2450 g and the length was 48cm.
He was the second child of healthy, intelligent parents. His parents were not related and his elder brother was normal.
There was no family history of thyroid disease. He was a dull, apathetic child. His height was 71.3cm (-1.6 SD) and his weight was 8.2kg (-2.3 SD). The skin was dry and sallow. The thyroid gland was not palpable. Systolic murmur was heard at the 3rd and 4th intercostal spaces to the left of the sternum. Umbilical hernia was present. The abdomen was protruding, the liver and spleen were not enlarged. There were no teeth. Neuro- (Wilkins, 1965) .
Although there is need for same caution in the use of T3 in the initial treatment of congenital hypothyroidism, the use of rapid acting T3 capable of quickening the induction of the euthyroid state is described (Malvaux, 1981) .
With sufficient care, T3 may be a safe drug for initial and long term treatment of congenital hypothyroidism (Petricciani et al., 1971; Federman et al., 1958) .
Even when serum T3 levels exceeded the upper limit of the normal range, symptoms of hyperthyroidism did not appear, probably because the rise in T3 was only transient. Serum T4 levels, essentially non-detectable, may be related to the lack of signs of hyperthyroidism.
Considerable variation in serum T3 may influence delicate body functions, although NIIMI et al. Endocrinol. Japon. February 1985 T3 was apparently free of unfavorable effects on the heart in this case with VSD. In this case the long term use of T3 was associated with a clinical course quite indistinguishable from that of patients treated with other thyroid hormone preparations such as desiccated thyroid and T4 (Niimi and Nakajima, 1977) .
T4 is now generally accepted as the treatment of choice in hypothyroidism, because of its greater reliability. However, our experience presented here suggests the possibility of safe and adequate long term administration of T3.
